Satellite Companies

We work with a consortium of satellite companies to expand our drugs and technologies outside our primary areas of focus, allowing us to expand the therapeutic range of antisense drugs. For example, Regulus is a satellite company partner that we co-founded to discover and develop antisense drugs targeting microRNAs.

We also form satellite company partnerships focused on developing and advancing certain RNA-targeting therapeutic technologies and take advantage of our dominant RNA-targeting intellectual property estate, and leverage our investments in our core technologies. These collaborations typically involve a cross-license between us and our partner and allow us to participate in newly emerging approaches to RNA-targeting therapeutics and augment our active programs in these areas.